A Multi-Center, Double Dummy, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5mg to Amlodipine 5mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5mg Monotherapy.

Trial Profile

A Multi-Center, Double Dummy, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5mg to Amlodipine 5mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5mg Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Amlodipine
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jun 2010 Results have been presented at the 17th World Congress of Cardiology.
    • 14 May 2010 Results published in Current Medical Research and Opinion.
    • 28 Oct 2008 Novartis Pharmaceuticals added as trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top